USRE28636E - Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine - Google Patents

Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine Download PDF

Info

Publication number
USRE28636E
USRE28636E US43757774A USRE28636E US RE28636 E USRE28636 E US RE28636E US 43757774 A US43757774 A US 43757774A US RE28636 E USRE28636 E US RE28636E
Authority
US
United States
Prior art keywords
pyrimidine
methyl
sulfanilamidoisoxazole
pharmaceutically acceptable
trimethoxybenzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Priority to US43757774 priority Critical patent/USRE28636E/en
Application granted granted Critical
Publication of USRE28636E publication Critical patent/USRE28636E/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine

Definitions

  • ABSTRACT Antibacterial compositions containing 5-methyl-3- sulfanilamidoisoxazole and 2.4-diamino5-(3,4.5- trimethoxybenzyl)-pyrimidine are described.
  • a therapeutically active antibacterial composition comprising 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino-5 -(3,4,5 trimethoxybenzyl) pyrimidine or a salt thereof with a pharmaceutically acceptable acid.
  • the sulfonamide, 5 methyl 3 sulfanilamidoisoxazole, and salts thereof with pharmaceutically acceptable bases are known antibacterial compounds.
  • various microorganisms which are at first susceptible to treatment with wellknown sulfonamides, develop a resistance which ultimately results in drug-fast strains.
  • the present invention relates to pharmaceutical compositions containing 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid useful in the treatment of bacterial infections in warmblooded animals.
  • the invention relates to pharmaceutical compositions, in suitable oral dosage forms, which compositions comprise 5-methyl- 3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4 diamino5- (3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid useful in the treatment of bacterial'infections in warm-blooded animals.
  • embodiments of the invention reside in the formulation of pharmaceutical compositions into suitable oral dosage forms and in the use of such combinations in the treatment of resistant bacterial infections, such as those with Proteus vulgaris in warmblooded animals.
  • salts thereof with pharmaceutically acceptable bases utilized throughout the present specification to denote salts of 5-methyl-3-sulfanilamidoisoxazole preferably includes those formed utilizing an alkali metal base, such as sodium hydroxide, potassium hydroxide, etc.
  • salts thereof with pharmaceutically acceptable acids utilized throughout the present specification to denote salts of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine preferably includes those formed utilizing mineral acids, such as hydrochloric acid, sulfuric acid, etc.; and organic acids, such as acetic acid, citric acid, lactic acid, maleic acid, salicylic acid, etc.
  • compositions of this invention are prepared simply by admixing 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino 5 (3,4,5 trimethoxybenzyl)pyrimidine or a salt thereof with pharmaceutically acceptable acid.
  • compositions of this invention can be compressed by usual methods into single or multi-layer tablets.
  • preparations can be produced in the form of coated tablets.
  • preparations of this invention can be provided in the form of hard-shell capsules.
  • various oral dosage forms of the present compositions are prepared by the conventional procedures and techniques of the art. The applicability of such methods and techniques to the formulation of the compositions of the present invention will be readily apparent to those skilled in the art.
  • each active component of the mixture individually.
  • each of the components into separate dosage forms in accordance with procedures hereinbefore and hereinafter described for the combination.
  • compositions of this invention can contain, as optional ingredients, any of the various adjuvants which are used ordinarily in the production of pharmaceutical preparations.
  • fillers such as coprecipitated aluminum hydroxide-calcium carbonate, dicalcium phosphate or lactose
  • disintegrating agents such as maize starch
  • lubricating agents such as talc, calcium stearate, and the like.
  • compositions of this invention can contain from about 1 to about 30 parts of 5 methyl 3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof to one part of 2,4-diamino-5- (3,4,5 trimethoxybenzyl)pyrimidine or an equivalent amount of salt thereof, preferably from about 5 to about 15 parts of 5 methyl 3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof to one part of 2,4-diamino 5 (3,4,5-trimethoxybenzyl)pyrimidine or an equivalent amount of salt thereof.
  • composition of the present invention can be administered in unit dosage forms which contain 500 mg.
  • S-methyl-3-sulfanilamidoisoxazole or an equivalent amount of a salt thereof and from about 25 mg. to about l mg. of Z,4-diamino--(3,4.5 trimethoxybenzyl )pyrimidine or an equivalent amount of a salt thereof.
  • a unit dosage form which will contain from about 250 mg. to about 750 mg. of 5-methyl-3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof and from about l2.5 mg. to about 75 mg. of 2.4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or an equivalent amount of a salt thereof.
  • any such unit dosage form will be administered to a warm-blooded animal will vary, depending upon the quantity of medicament present therein and the needs and requirements of the warmblooded animal. Under ordinary circumstances, however, up to about a total of 60 mg./kg. of 5-methyl-3-sulfanilamidoisoxazole and up to about a total of 8 mgjkg. of 2,4-diamino-5-(3,4,S-trimethoxybenzyl)pyrimidine, in combination, can be administered daily in several oral doses.
  • Example 1 The activity of the combination of the present invention against resistant organisms was demonstrated by the following procedure:
  • IQ inoculum was diluted in 5% hog gastric mucin.
  • test animals were treated orally by gavage with 1.0 ml. of.the desired concentration of the single drug or the appropriate sulfonamide-pyrimidine combination in 1% carboxymethyleellulose.
  • Example 2 expectedly been found to be particularly useful in the treatment of bacterial infections in warm-blooded animals which are caused by resistant strains of bacteria.
  • Example 5 Per tablet. Per Capsule. Tablet formulation: mg 5 Capsule formulation: mg.
  • the milled, wet granules were dried at 110 F.
  • the dry granules were passed through a Model D Fitzmill at medium speed with knives forward using a No. l2 screen.
  • the milled, dry granulation was transferred to a suitable blender, and 15 parts of talc and 5 parts of magnesium stearate were added and mixed until uniform.
  • the granulation was compressed on a BB2 Rotary.
  • the punches used were l5/23", flat beveled edge scored.
  • trimethoxybenzyl)pyrimidine 35 parts of lactose, 35 parts of cornstarch and 5 parts of magnesium stearate were mixed until thoroughly blended in a suitable size container.
  • the powder was filled in No. 2, two piece, hard shell gelatin capsules to an approximate fill weight of 350 mg. using a Parke Davis capsulating machine.
  • a therapuetic antibacterial composition elTective in the treatment of sulfamethoxazole resistant bacterial infections comprising from about I to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pryimidine and salts thereof with pharmaceutically acceptable acids]
  • a composition in accordance with claim 1 which contains pharmaceutical adjuvant materials.
  • composition in accordance with claim 1 wherein the sulfonamide is 5-methyl-3-sulfanilamidoisoxazole] [4.
  • a compositionn in accordance with claim 3 wherein the pyrimidine is 2,4-diamino-5-(3.4,5-trimethoxybenzyD-pyrimidine] [5.
  • a composition in accordance with claim 1 comprising from about 5 to about 15 parts of 5-methyl-3- sulfoniamidoisoxazole and one part of 2,4-diamino-5- (3,4,5-trimethoxybenzyl) pyrimidine] [6.
  • a therapeutic antibacterial composition effective in the treatment of bacterial infections in warmblooded animals which are caused by sulfamethoxazole resistant strains of bacteria for internal administration in shaped dosage unit form comprising from about 250 mg. to about 750 mg. of 5-methyl-3-sulfanilamidoisoxazole or an alkali metal salt thereof with a pharmaceutically acceptable base and from about 12.5 mg. to about mg. of 2,4-diamino-5(3,4,5-trimethoxybenzyl) pyrimidine or a salt thereof with a pharmaceutically acceptable acid] 7.
  • a process for treating a warm-blooded animal afflicted with a bacterial disease caused by sulfomethoxazole resistant strains of bacteria comprising orally administering to said warm-blooded animal a therape utically effective amount of a composition comprising from about 1 to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl 3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4- diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine and salts thereof with pharmaceutically acceptable acids.
  • a composition comprising from about 1 to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl 3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4- diamino-5
  • the f about 1 mg to 75 mg f 2 4 5- 3 4 5 therapeutically effective amount of the composition comprises from about 250 mg. to about 750 mg. of 5- methyl-3-sulfanilamidoisoxazole or an alkali metal salt Pha'macem'cally accepmble thereof with a pharmaceutically gcceptable base and 5 trimethoxybenzyl) pyrimidine or a salt thereof with a UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. Reissue 28,636

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antibacterial compositions containing 5-methyl-3sulfanilamidoisoxazole and 2,4-diamino-5-(3,4,5trimethoxybenzyl)-pyrimidine are described.

Description

United States Patent n91 Grunberg [Ill E Re. 28,636
[ 1 Reissued Dec. 2, 1975 I ANTIBACTERIAL COMPOSITION CONTAINING S-METHYL-S- SULFANILAMIDOISOXAZOLE AND TRIMETHOXYBENYL PYRIMIDINE [75] Inventor: Emanuel Grunberg, North Caldwell,
[73] Assignee: Hoffmann-La Roche Inc., Nutley,
[22] Filed: Jan. 28, I974 [2]] App]. No.: 437,577
Related US. Patent Documents Reissue of:
[64] Patent No.2 3,515,783
Issued: June 2, I970 App]. No.: 676,700
Filed: Oct. 20, I967 [52] US. Cl 424/229; 424/251 [5 1] Int. Cl. A6IK 31/505 [58] Field of Search 424/251, 229
OTHER PUBLICATIONS Derwent Basic No. 21,416. of Sov African Pat. 65/5618.
Primary ExaminerV. D. Turner Attorney. Agent, or FirmSarnuel L, Welt; Jon S. Saxe; Gerald S. Rosen [57] ABSTRACT Antibacterial compositions containing 5-methyl-3- sulfanilamidoisoxazole and 2.4-diamino5-(3,4.5- trimethoxybenzyl)-pyrimidine are described.
2 Claims, N0 Drawings ANTIBACTERIAL COMPOSITION CONTAINING -METHYL-3-SULFANILAMIDOISOXAZOLE TRIMETHOXYBENYL PYRIMIDINE Matter enclosed in heavy brackets I: appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.
BRIEF SUMMARY OF THE INVENTION A therapeutically active antibacterial composition comprising 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino-5 -(3,4,5 trimethoxybenzyl) pyrimidine or a salt thereof with a pharmaceutically acceptable acid.
BACKGROUND OF THE INVENTION The sulfonamide, 5 methyl 3 sulfanilamidoisoxazole, and salts thereof with pharmaceutically acceptable bases, are known antibacterial compounds. Moreover, it is also known that various microorganisms, which are at first susceptible to treatment with wellknown sulfonamides, develop a resistance which ultimately results in drug-fast strains.
Accordingly, it was of particular interest to develop a combination of sulfonamide and activator which is effective against such sulfonamide resistant strains. Unexpectedly, it has now been found that the combination of this invention is medicinally effective, for example, against a sulfonamide resistant strain of Proteus vulga- 2,4 diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine and a process for the preparation thereof are disclosed in U.S. Pat. No. 2,909,522. 5-methyl-3-sulfanilamidoisoxazole and a process for the preparation thereof are disclosed in U.S. Pat. No. 2,888,455.
DETAILED DESCRIPTION In its most comprehensive embodiment, the present invention relates to pharmaceutical compositions containing 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid useful in the treatment of bacterial infections in warmblooded animals.
In a more particular embodiment, the invention relates to pharmaceutical compositions, in suitable oral dosage forms, which compositions comprise 5-methyl- 3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4 diamino5- (3,4,5-trimethoxybenzyl)pyrimidine or a salt thereof with a pharmaceutically acceptable acid useful in the treatment of bacterial'infections in warm-blooded animals.
Still further, embodiments of the invention reside in the formulation of pharmaceutical compositions into suitable oral dosage forms and in the use of such combinations in the treatment of resistant bacterial infections, such as those with Proteus vulgaris in warmblooded animals.
The expression salts thereof with pharmaceutically acceptable bases utilized throughout the present specification to denote salts of 5-methyl-3-sulfanilamidoisoxazole, preferably includes those formed utilizing an alkali metal base, such as sodium hydroxide, potassium hydroxide, etc.
The expression salts thereof with pharmaceutically acceptable acids utilized throughout the present specification to denote salts of 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine, preferably includes those formed utilizing mineral acids, such as hydrochloric acid, sulfuric acid, etc.; and organic acids, such as acetic acid, citric acid, lactic acid, maleic acid, salicylic acid, etc.
The compositions of this invention are prepared simply by admixing 5-methyl-3-sulfanilamidoisoxazole or a salt thereof with a pharmaceutically acceptable base and 2,4-diamino 5 (3,4,5 trimethoxybenzyl)pyrimidine or a salt thereof with pharmaceutically acceptable acid.
The mixture is ultimately embodied in a suitable oral dosage form. For example, the compositions of this invention can be compressed by usual methods into single or multi-layer tablets. Moreover, the preparations can be produced in the form of coated tablets. Additionally, the preparations of this invention can be provided in the form of hard-shell capsules. In general, the various oral dosage forms of the present compositions are prepared by the conventional procedures and techniques of the art. The applicability of such methods and techniques to the formulation of the compositions of the present invention will be readily apparent to those skilled in the art.
It is also within the scope of this invention to administer each active component of the mixture individually. Thus, it is possible suitably to formulate each of the components into separate dosage forms in accordance with procedures hereinbefore and hereinafter described for the combination.
In addition to the therapeutically active ingredients mentioned heretofore, the compositions of this invention can contain, as optional ingredients, any of the various adjuvants which are used ordinarily in the production of pharmaceutical preparations. Thus, for example, in formulating the present compositions into the desired oral dosage forms, one may use, as optional ingredients, fillers, such as coprecipitated aluminum hydroxide-calcium carbonate, dicalcium phosphate or lactose; disintegrating agents, such as maize starch; and lubricating agents, such as talc, calcium stearate, and the like. It should be fully understood, however, that the optional ingredients herein named are given by way of example only and that the invention is not restricted to the use hereof. On the contrary, other such adjuvants, the identity and use of which are well known in the art, can be, and are, employed in carrying out this invention.
The ratios in which the therapeutically active components are utilized in the compositions of this invention can be varied within wide limits. For example, the compositions can contain from about 1 to about 30 parts of 5 methyl 3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof to one part of 2,4-diamino-5- (3,4,5 trimethoxybenzyl)pyrimidine or an equivalent amount of salt thereof, preferably from about 5 to about 15 parts of 5 methyl 3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof to one part of 2,4-diamino 5 (3,4,5-trimethoxybenzyl)pyrimidine or an equivalent amount of salt thereof.
The composition of the present invention can be administered in unit dosage forms which contain 500 mg.
of S-methyl-3-sulfanilamidoisoxazole or an equivalent amount of a salt thereof and from about 25 mg. to about l mg. of Z,4-diamino--(3,4.5 trimethoxybenzyl )pyrimidine or an equivalent amount of a salt thereof. However. it is also within the scope of this invention to utilize a unit dosage form which will contain from about 250 mg. to about 750 mg. of 5-methyl-3 sulfanilamidoisoxazole or an equivalent amount of a salt thereof and from about l2.5 mg. to about 75 mg. of 2.4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine or an equivalent amount of a salt thereof. The frequency with which any such unit dosage form will be administered to a warm-blooded animal will vary, depending upon the quantity of medicament present therein and the needs and requirements of the warmblooded animal. Under ordinary circumstances, however, up to about a total of 60 mg./kg. of 5-methyl-3-sulfanilamidoisoxazole and up to about a total of 8 mgjkg. of 2,4-diamino-5-(3,4,S-trimethoxybenzyl)pyrimidine, in combination, can be administered daily in several oral doses.
The foregoing, notwithstanding, it should be fully understood that the dosages set forth herein are exemplary only and they do not, to any extent, limit the scope or practice of the present invention. As indicated Example 1 The activity of the combination of the present invention against resistant organisms was demonstrated by the following procedure:
IQ inoculum was diluted in 5% hog gastric mucin.
For all infections, the test animals were treated orally by gavage with 1.0 ml. of.the desired concentration of the single drug or the appropriate sulfonamide-pyrimidine combination in 1% carboxymethyleellulose.
l5 Treatment consisted of a total of 4 doses administered once daily for 4 days with the first dose administered 5l0 minutes after infection. When combinations were administered, varying concentrations of sulfonamide were prepared in the presence of an inactive concentration of 2,4-diamino-S-(3,4,5-trimethoxybenzyl)- pyrimidine. The experimental observation period was 14 days. Heart blood from mice succumbing during this period of time was cultured on appropriate solid media to determine the presence or absence of the infecting 25 organism. Results obtained are given in Table I.
TABLE I {The activity of sulfamethoxazole' alone and in combination with trimethoprim against infection of mice with strain of Proteus \ulgun's resistant to sulfamethoxazole is set forth below} Combination Trimeth- Trimeth- Sulfameth Sulfamethoprim Dose, oprim Dose, oxazole Dose, Survival oxazole Dose. mgJkg. Survival mg/kg. Survival Organism mgjkg per 05 Rate mgikg. per 05 Plus per 05 Rate per us Rate Proteus \ulgan's 1,000 0/8 L000 Plus 50 6/8 200 N8 200 do. 50 7/8 I00 0T8 I00 do. 50 7/8 50 1/8 50 do, 50 8/8 50 0/8 20 20 do. 50 2/8 CD rag/kg. per 05 I ,000 37 50 S-methyl-3-sulfanilamidoisoxazole- LD in mice P.O.=2 25U mgJkg after 72 hours. 2.4 diamino5-(3,4.5-trimethoxybenzyl)pyrimidine -LDN in mice P.0.=2,350 rug/kg. after 72 hours. "No of sunivorsiNo. of infected and treated animals CD was calculated according to method of Reed and Mueneh, Am. J. Hyg. 27: 493-497, May 1938.
hereinbefore, the combination of this invention has un- Example 2 expectedly been found to be particularly useful in the treatment of bacterial infections in warm-blooded animals which are caused by resistant strains of bacteria.
The invention will be understood better by reference to the following examples which are given for illustration purposes and are not meant to limit the invention.
The unexpectedly increased activity of 5-methyl-3- sulfanilamidoisoxazole when combined with 2,4- diamino-5-(3,4,S-trimethoxybenyzyl)pyrimidine in the 50 treatment of various bacterial infections, was demonstrated utilizing the procedure set forth in Example 1. Results obtained are given in Table ll.
TABLE I] [The antibacterial effect of sulfamethoxazole alone and in combination with trimethoprim against bacterial infections in mice is set forth below} am g /kg. per os Trimetho- Sulfameth prim Dose, Sulfamethlncreased oxazole Dose. mg/kg. oxazole Dose, Activity Organism mg/kg. per 05 per os Plus mg/kg. per os (X-fOILl) S. hemol vlicus No. 4 200 50 Plus 32 s 2 D, pneurnmiiue No. 6301 1 .000 50 do. 463 12 S. uureus Smith 154 do. 6.25 246 E. coli No. 257 I05 10 do. 5.3 P. i'ulgal'h No. 190 2 do. 9 2.8 P. aerugimlsn B 107 do. 78 l.3
Increased Ac tiv it tx fuld Dose Sulfonamide alone Dose Sulfonamidc in Combination These doese of trimethoprim when administered alone are inactive Example 3 Example 5 Per tablet. Per Capsule. Tablet formulation: mg 5 Capsule formulation: mg.
5 methyl-3-sulfanilamidoisoxazole 505 smfiihl'lr3'sulfanilamllluis0xfllfllfi 2.4-diamino5 3.4,5-trimethoxybenz l) 2.4:diam|n-5-l 3.4.i-trimethoxybenzyl) pyrimidine pyrimidlne 25 Cornstarch 30 Lactose 3 5 Lactose 82 Cornstarch 35 admin p Magnesium stearate 5 Talcum g Total 350 Magnesium stearate 5 Total 700 Preparation-250 parts of 5-methyl-3-sull5 fanilamidoisoxazole, 25 parts of 2,4-diamino-5-(3,4,5-
Preparation-505 parts of 5-methyl-3-sulfanilamidoisoxazole, 5| parts of 2,4-diamino-5-(3,4,5- trimethoxybenzyl pyrimidine and 82 parts of lactose were thoroughly mixed in suitable blending equipment and granulated with a solution containing l2 parts of gelatin. The moist mass was passed through a No. 12 screen, and the granules were dried on paper-lined trays overnight. The dried granules were passed through a No. 14 screen and placed in a suitable mixer. Thereafter, 12 parts of talcum and 5 parts of magnesium stearate were added and blended. The granulation was compressed into tablets weighing approximately 700 mg. each, using punches having an approximate diameter of 12.7 mm. /2"). the final tablet thickness was about 5.35 mm.
Preparation-252.5 parts of S-methyl-3-sulfanilamidoisoxazole and 63.75 parts of 2,4-diamino- 5-(3,4,5-trimethoxybenzyhpyrimidine, 73.75 parts of lactose, 70 parts of cornstarch U.S.P. and 70 parts of prehydrolyzed cornstarch were transferred to a suitable mixer and blended until unifonn. The blended powders were passed through a Model D Fitzmill at high speed with hammers forward using a No. ()0 screen. This premix was transferred to a suitable blender. The blended powders were granulated with distilled water. The wet granulation was passed through a Model D Fitzmill with knives forward at slow speed using a No. 4B screen. The milled, wet granules were dried at 110 F. The dry granules were passed through a Model D Fitzmill at medium speed with knives forward using a No. l2 screen. The milled, dry granulation was transferred to a suitable blender, and 15 parts of talc and 5 parts of magnesium stearate were added and mixed until uniform. The granulation was compressed on a BB2 Rotary. The punches used were l5/23", flat beveled edge scored.
trimethoxybenzyl)pyrimidine, 35 parts of lactose, 35 parts of cornstarch and 5 parts of magnesium stearate were mixed until thoroughly blended in a suitable size container. The powder was filled in No. 2, two piece, hard shell gelatin capsules to an approximate fill weight of 350 mg. using a Parke Davis capsulating machine.
I claim:
[1. A therapuetic antibacterial composition elTective in the treatment of sulfamethoxazole resistant bacterial infections comprising from about I to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pryimidine and salts thereof with pharmaceutically acceptable acids] I: 2. A composition in accordance with claim 1 which contains pharmaceutical adjuvant materials. J
[3. A composition in accordance with claim 1 wherein the sulfonamide is 5-methyl-3-sulfanilamidoisoxazole] [4. A compositionn in accordance with claim 3 wherein the pyrimidine is 2,4-diamino-5-(3.4,5-trimethoxybenzyD-pyrimidine] [5. A composition in accordance with claim 1 comprising from about 5 to about 15 parts of 5-methyl-3- sulfoniamidoisoxazole and one part of 2,4-diamino-5- (3,4,5-trimethoxybenzyl) pyrimidine] [6. A therapeutic antibacterial composition effective in the treatment of bacterial infections in warmblooded animals which are caused by sulfamethoxazole resistant strains of bacteria for internal administration in shaped dosage unit form comprising from about 250 mg. to about 750 mg. of 5-methyl-3-sulfanilamidoisoxazole or an alkali metal salt thereof with a pharmaceutically acceptable base and from about 12.5 mg. to about mg. of 2,4-diamino-5(3,4,5-trimethoxybenzyl) pyrimidine or a salt thereof with a pharmaceutically acceptable acid] 7. A process for treating a warm-blooded animal afflicted with a bacterial disease caused by sulfomethoxazole resistant strains of bacteria comprising orally administering to said warm-blooded animal a therape utically effective amount of a composition comprising from about 1 to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl 3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4- diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine and salts thereof with pharmaceutically acceptable acids.
8. A process in accordance with claim '7 wherein the f about 1 mg to 75 mg f 2 4 5- 3 4 5 therapeutically effective amount of the composition comprises from about 250 mg. to about 750 mg. of 5- methyl-3-sulfanilamidoisoxazole or an alkali metal salt Pha'macem'cally accepmble thereof with a pharmaceutically gcceptable base and 5 trimethoxybenzyl) pyrimidine or a salt thereof with a UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. Reissue 28,636
DATED December 2, 1975 lNVENTOR( 3 EMANUEL GRUNBERG It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Title page No. [54] change title to read as follows:
METHOD OF TREATING RESISTANT BACTERIAL INFECTIONS WITH A COMPOSITION CONTAINING 5 IVIETHYL-3-SULFANIL AMIDOISOXAZOLE AND TRIMETHOXYBENZYL PYRIMIDINE Column 6, line 43 "sulfoniamidoisoxazole" should be sulfanilamidoisoxazole Signed and Scaled this A ties r:
C. MARSHALL DANN (ummissruner of Parenr: and Trademarks RUTH C. MASON Arresting Officer

Claims (2)

  1. 7. A process for treating a warm-blooded animal afflicted with a bacterial disease caused by sulfomethoxazole resistant strains of bacteria comprising orally administering to said warm-blooded animal a therapeutically effective amount of a composition comprising from about 1 to about 30 parts of a sulfonamide selected from the group consisting of 5-methyl-3-sulfanilamidoisoxazole and alkali metal salts thereof with pharmaceutically acceptable bases and one part of a pyrimidine selected from the group consisting of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine and salts thereof with pharmaceutically acceptable acids.
  2. 8. A process in accordance with claim 7 wherein the therapeutically effective amount of the composition comprises from about 250 mg. to about 750 mg. of 5-methyl-3-sulfanilamidoisoxazole or an alkali metal salt thereof with a pharmaceutically acceptable base and from about 12.5 mg. to 75 mg. of 2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine or a salt thereof with a pharmaceutically acceptable acid.
US43757774 1967-10-20 1974-01-28 Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine Expired USRE28636E (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US43757774 USRE28636E (en) 1967-10-20 1974-01-28 Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67670067A 1967-10-20 1967-10-20
US43757774 USRE28636E (en) 1967-10-20 1974-01-28 Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine

Publications (1)

Publication Number Publication Date
USRE28636E true USRE28636E (en) 1975-12-02

Family

ID=24715613

Family Applications (2)

Application Number Title Priority Date Filing Date
US676700A Expired - Lifetime US3515783A (en) 1967-10-20 1967-10-20 Antibacterial composition containing 5-methyl - 3 - sulfanilamidoisoxazole and trimethoxybenzyl pyrimidine
US43757774 Expired USRE28636E (en) 1967-10-20 1974-01-28 Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US676700A Expired - Lifetime US3515783A (en) 1967-10-20 1967-10-20 Antibacterial composition containing 5-methyl - 3 - sulfanilamidoisoxazole and trimethoxybenzyl pyrimidine

Country Status (2)

Country Link
US (2) US3515783A (en)
CA (1) CA1003331B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279899A (en) 1977-07-06 1981-07-21 Basf Aktiengesellschaft Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds
US4333936A (en) 1978-07-03 1982-06-08 Basf Aktiengesellschaft Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1044231B (en) * 1972-03-16 1980-03-20 Hoffmann La Roche COMBINATION OF ACTIVE SUBSTANCES USEFUL TO FIGHT BACTERIA INFECTIONS GRAM POSITIVE AND GRAN NEGATIVE
DE2342213C3 (en) * 1972-10-12 1979-10-18 F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) Use of potentiated sulfonamides in the treatment or prevention of fish infections
CA2598668A1 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics and symptomatic relief agents

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909522A (en) * 1957-02-21 1959-10-20 Burroughs Wellcome Co Trialkoxybenzylpyrimidines and method
FR1453056A (en) * 1964-11-12 1966-04-15 Hoffmann La Roche Process for the preparation of pyrimidine derivatives
US3249603A (en) * 1960-08-09 1966-05-03 Hoffmann La Roche Novel pyrimidine sulfanilamides and processes for their preparation
BE671982A (en) * 1964-11-12 1966-05-09

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909522A (en) * 1957-02-21 1959-10-20 Burroughs Wellcome Co Trialkoxybenzylpyrimidines and method
US3249603A (en) * 1960-08-09 1966-05-03 Hoffmann La Roche Novel pyrimidine sulfanilamides and processes for their preparation
FR1453056A (en) * 1964-11-12 1966-04-15 Hoffmann La Roche Process for the preparation of pyrimidine derivatives
BE671982A (en) * 1964-11-12 1966-05-09
NL6514178A (en) * 1964-11-12 1966-05-13
US3341541A (en) * 1964-11-12 1967-09-12 Hoffmann La Roche Processes and intermediates for pyrimidine derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Derwent Basic No. 21,416, of So. African Pat. 65/5618 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4279899A (en) 1977-07-06 1981-07-21 Basf Aktiengesellschaft Benzylpyrimidines, processes for their manufacture, and drugs containing the said compounds
US4333936A (en) 1978-07-03 1982-06-08 Basf Aktiengesellschaft Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof

Also Published As

Publication number Publication date
CA1003331B (en) 1977-01-11
US3515783A (en) 1970-06-02

Similar Documents

Publication Publication Date Title
US3898328A (en) Dry stable composition for the treatment of scours and dehydration
EP0011489B1 (en) An analgesic effervescent powder and process for its preparation
EP0941088B1 (en) Use of conjugated linoleic acid to enhance natural killer lymphocyte function
JPH08508045A (en) Pharmaceutical composition for prevention and treatment of cancerous disease, and method for producing the same
EP0011490B1 (en) Analgesic tablet and process for its preparation
USRE28636E (en) Antibacterial composition containing 5-methyl-3-sulfanilamidoisoxazole and trimethoxybenyl pyrimidine
US3996356A (en) Composition containing 5-sulfanilamido-3,4-dimethylisoxazole and a trimethoxybenzyl pyrimidine
US2438106A (en) Peroral penicillin compositions
NZ224550A (en) Anticoccidial compositions containing an ionophorous polyether and frenolicin b
JPH0140009B2 (en)
EP0414688B1 (en) Process for regulating the absorption rate of drugs and a pharmaceutical formulation
JPS6114124B2 (en)
US2967130A (en) p-sulfamyl beta-hydroxyethyl carbanilate diuretic compositions
US3121044A (en) Three-layer compressed penicillin tablet
US4125610A (en) Antibacterial compositions
GB983588A (en) Improvements relating to pharmaceutical compositions containing pantothenic acid
US3864486A (en) Therapeutic compositions of bromazepam and sulpiride
CA1143658A (en) Skeletal muscle relaxant
US3519712A (en) Therapeutic compositions comprising n-methylglucamine and coumermycin or salts thereof
WO1999056738A1 (en) Use of triclosan for the treatment of helicobacter pylori infections
US3642993A (en) Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension
US3138529A (en) Tetracycline antibiotic compositions for oral use
US3356571A (en) Potentiation of tetracycline by polyacrylic acid or hydrolyzed polyacrylonitrile
US3737546A (en) Use of ipronidazole in combatting swine dysentery
US3740423A (en) Protection of the colon of mammals during treatment with antibiotics by simultaneous administration of nystatin and torulopsis tropsis